{"url_path":"/sec/cccc/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-055490-index.html","accession_number":"0001628280-26-055490","cik":"0001662579","ticker":"CCCC","issuer_name":"C4 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-055490-index.html","primary_entity_key":"0001662579","primary_entity_name":"C4 Therapeutics, Inc."},"word_count":123,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.\n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n[Press release issued August 11, 2026](cccc-20260811xexx991.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nC4 Therapeutics, Inc.\n\nDate: August 11, 2026\n\nBy:\n\n/s/ Kendra R. Adams\n\nKendra R. Adams\n\nChief Financial Officer, Head of Corporate Affairs, and Treasurer"}